Paolo Rovero

List of Publications by Year
in descending order

275 papers	6,504 citations	81900 39 h-index	91884 69 g-index
284 all docs	284 docs citations	284 times ranked	4845 citing authors

#	Article	IF	Citations
1	First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 592-596.	5.2	14
2	Reactivity of Rheumatoid Arthritis-Associated Citrulline-Dependent Antibodies to Epstein-Barr Virus Nuclear Antigen1-3. Antibodies, 2022, 11, 20.	2.5	5
3	Peptide Antibody Reactivity to Homologous Regions in Glutamate Decarboxylase Isoforms and Coxsackievirus B4 P2C. International Journal of Molecular Sciences, 2022, 23, 4424.	4.1	3
4	Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas. Frontiers in Immunology, 2022, 13, 856033.	4.8	5
5	A SARSâ€“CoV-2 Spike Receptor Binding Motif Peptide Induces Anti-Spike Antibodies in Mice andIs Recognized by COVID-19 Patients. Frontiers in Immunology, 2022, 13, .	4.8	2
6	Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry. Chemistry and Biodiversity, 2021, 18, e2000833.	2.1	18
7	An Optimized Scalable Fully Automated Solid-Phase Microwave-Assisted cGMP-Ready Process for the Preparation of Eptifibatide. Organic Process Research and Development, 2021, 25, 552-563.	2.7	7
8	Susceptibility of cosmeceutical peptides to proteases activity: Development of dermal stability test by LC-MS/MS analysis. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113775.	2.8	4
9	Cross-reactive peptide epitopes of Enterovirus Coxsackie B4 and human glutamic acid decarboxylase detecting antibodies in latent autoimmune diabetes in adults versus type 1 diabetes. Clinica Chimica Acta, 2021, 515, 73-79.	1.1	3
10	Triazole-Modified Peptidomimetics: An Opportunity for Drug Discovery and Development. Frontiers in Chemistry, 2021, 9, 674705.	3.6	16
11	Peptides and Peptidomimetics as Inhibitors of Enzymes Involved in Fibrillar Collagen Degradation. Materials, 2021, 14, 3217.	2.9	6
12	Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated Î±-Enolase Peptides as a Function of Epitope Structure and Composition. Antibodies, 2021, 10, 27.	2.5	4
13	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. Scientific Reports, 2021, 11, 16393.	3.3	3
14	ELISA based on peptide antigens reproducing cross-reactive viral epitopes to detect antibodies in latent autoimmune diabetes in adults vs. type 1 diabetes. MethodsX, 2021, 8, 101452.	1.6	1
15	An Optimized Safe Process from Bench to Pilot cGMP Production of API Eptifibatide Using a Multigram-Scale Microwave-Assisted Solid-Phase Peptide Synthesizer. Organic Process Research and Development, 2021, 25, 2754-2771.	2.7	1
16	Selective capture of antiâ€Nâ€glucosylated NTHi adhesin peptide antibodies by a multivalent dextran conjugate. ChemBioChem, 2021, , .	2.6	4
17	Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Frontiers in Chemistry, 2020, 8, 572923.	3.6	33
18	Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. Processes, 2020, 8, 1539.	2.8	18

#	Article	IF	Citations
19	A Multiple N-Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis. Brain Sciences, 2020, 10, 453.	2.3	5
20	Hyperglucosylated adhesinâ€derived peptides as antigenic probes in multiple sclerosis: Structure optimization and immunological evaluation. Journal of Peptide Science, 2020, 26, e3281.	1.4	3
21	Triterpene glycosides from Blighia welwitschii and evaluation of their antibody recognition capacity in multiple sclerosis. Phytochemistry, 2020, 176, 112392.	2.9	4
22	Onâ€resin microwaveâ€assisted copperâ€catalyzed azideâ€alkyne cycloaddition of H1â€relaxin B single chain â€˜stapledâ€™ analogues. Peptide Science, 2020, 112, e24159.	1.8	7
23	An Optimised Di-Boronate-ChemMatrix Affinity Chromatography to Trap Deoxyfructosylated Peptides as Biomarkers of Glycation. Molecules, 2020, 25, 755.	3.8	10
24	Modeling interaction between gp120 HIV protein and CCR5 receptor. Journal of Peptide Science, 2019, 25, e3142.	1.4	4
25	Humoral Response Against LLâ€37 in Psoriatic Disease: Comment on the Article by Yuan et al. Arthritis and Rheumatology, 2019, 71, 1964-1965.	5.6	3
26	Fine Mapping of Glutamate Decarboxylase 65 Epitopes Reveals Dependency on Hydrophobic Amino Acids for Specific Interactions. International Journal of Molecular Sciences, 2019, 20, 2909.	4.1	8
27	Just a spoonful of sugar: Short glycans affect protein properties and functions. Journal of Peptide Science, 2019, 25, e3167.	1.4	2
28	Glycoreplica peptides to investigate molecular mechanisms of immune-mediated physiological versus pathological conditions. Archives of Biochemistry and Biophysics, 2019, 663, 44-53.	3.0	5
29	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. Analytical Biochemistry, 2019, 566, 133-138.	2.4	7
30	Studies of membranotropic and fusogenic activity of two putative HCV fusion peptides. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 50-61.	2.6	3
31	Histone Protein Epitope Mapping for Autoantibody Recognition in Rheumatoid Arthritis. Methods in Molecular Biology, 2019, 1901, 221-228.	0.9	1
32	Study of Aberrant Modifications in Peptides as a Test Bench to Investigate the Immunological Response to Non-Enzymatic Glycation. Folia Biologica, 2019, 65, 195-202.	0.6	0
33	Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clinical Rheumatology, 2018, 37, 1407-1411.	2.2	20
34	Emerging Peptide Science in Italy. Peptide Science, 2018, 110, e24096.	1.8	0
35	Antibodies to post-translationally modified mitochondrial peptide PDC-E2(167â€“184) in type 1 diabetes. Archives of Biochemistry and Biophysics, 2018, 659, 66-74.	3.0	6
36	Serpin A1 and the modulation of type I collagen turnover: Effect of the Câ€terminal peptide 409â€“418 (SA1â€III) in human dermal fibroblasts. Cell Biology International, 2018, 42, 1340-1348.	3.0	7

#	Article	IF	Citations
37	Design, synthesis, and conformational studies of [DOTA]â€Octreotide analogs containing [1,2,3]triazolyl as a disulfide mimetic. Peptide Science, 2018, 110, e24071.	1.8	7
38	Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC)-Mediated Macrocyclization of Peptides: Impact on Conformation and Biological Activity. Current Topics in Medicinal Chemistry, 2018, 18, 591-610.	2.1	12
39	Structureâ€“Activity Relationship Studies, SPR Affinity Characterization, and Conformational Analysis of Peptides That Mimic the HNKâ€1 Carbohydrate Epitope. ChemMedChem, 2017, 12, 751-759.	3.2	5
40	Synthesis of dicarba-cyclooctapeptide Somatostatin analogs by conventional and MW-assisted RCM: A study about the impact of the configuration at C Î± of selected amino acids. Chemical Engineering and Processing: Process Intensification, 2017, 122, 365-372.	3.6	4
41	Multiplex determination of antigen specific antibodies with cell binding capability in a self-driven microfluidic system. Sensors and Actuators B: Chemical, 2017, 238, 1092-1097.	7.8	6
42	A novel DNA/histone H4 peptide complex detects autoantibodies in systemic lupus erythematosus sera. Arthritis Research and Therapy, 2016, 18, 220.	3.5	4
43	Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae. Scientific Reports, 2016, 6, 39430.	3.3	23
44	AB0500â€…A Novel DNA-Peptide Complex Detects Anti-DSDNA Antibodies in SLE Sera. Annals of the Rheumatic Diseases, 2016, 75, 1076.3-1076.	0.9	0
45	Serpinâ€…A1 Câ€Terminal Peptides as Collagen Turnover Modulators. ChemMedChem, 2016, 11, 1850-1855.	3.2	6
46	Label-free detection of immune complexes with myeloid cells. Clinical and Experimental Immunology, 2016, 185, 72-80.	2.6	6
47	Rett syndrome: An autoimmune disease?. Autoimmunity Reviews, 2016, 15, 411-416.	5.8	25
48	Epitope mapping of antiâ€myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwaveâ€assisted synthesis of the peptide antigens and ELISA screening. Journal of Peptide Science, 2016, 22, 52-58.	1.4	8
49	Production of peptides as generic drugs: a patent landscape of octreotide. Expert Opinion on Therapeutic Patents, 2016, 26, 485-495.	5.0	5
50	Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Lysyl-Peptidyl-Anthraquinone Conjugates. Bioconjugate Chemistry, 2016, 27, 247-256.	3.6	11
51	Serological and Genetic Evidence for Altered Complement System Functionality in Systemic Lupus Erythematosus: Findings of the GAPAID Consortium. PLoS ONE, 2016, 11, e0150685.	2.5	5
52	Characterization of NF-ÎºB Reporter U937 Cells and Their Application for the Detection of Inflammatory Immune-Complexes. PLoS ONE, 2016, 11, e0156328.	2.5	10
53	Lipoylated Peptides and Proteins. Topics in Heterocyclic Chemistry, 2015, , 1.	0.2	0
54	Antibody Recognition in multiple sclerosis and rett syndrome using a collection of linear and cyclic Nâ€glucosylated antigenic probes. Biopolymers, 2015, 104, 560-576.	2.4	15

#	Article	IF	Citations
55	Interaction Study of Phospholipid Membranes with an N-Glucosylated Î²-Turn Peptide Structure Detecting Autoantibodies Biomarkers of Multiple Sclerosis. Membranes, 2015, 5, 576-596.	3.0	5
56	Synthetic Peptides Reproducing Tissue Transglutaminaseâ€“Gliadin Complex Neo-epitopes as Probes for Antibody Detection in Celiac Disease Patientsâ€™ Sera. Journal of Medicinal Chemistry, 2015, 58, 1390-1399.	6.4	6
57	Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex: Toward a Peptide-Based Diagnostic Assay for Primary Biliary Cirrhosis. Journal of Medicinal Chemistry, 2015, 58, 6619-6629.	6.4	7
58	Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. Analytical and Bioanalytical Chemistry, 2015, 407, 7477-7485.	3.7	18
59	Synthesis of diastereomerically pure Lys(N^{Îµ}â€lipoyl) building blocks and their use in Fmoc/tBu solid phase synthesis of lipoylâ€containing peptides for diagnosis of primary biliary cirrhosis. Journal of Peptide Science, 2015, 21, 408-414.	1.4	10
60	Fingerprinting of anti-citrullinated protein antibodies (ACPA): specificity, isotypes and subclasses. Lupus, 2015, 24, 433-441.	1.6	11
61	Lipoylated Peptides and Proteins. Topics in Heterocyclic Chemistry, 2015, , 235-252.	0.2	0
62	Label-free method for anti-glucopeptide antibody detection in Multiple Sclerosis. MethodsX, 2015, 2, 141-144.	1.6	16
63	Surface Plasmon Resonance Method to Evaluate Anti-citrullinated Protein/Peptide Antibody Affinity to Citrullinated Peptides. Methods in Molecular Biology, 2015, 1348, 267-274.	0.9	6
64	pHâ€regulated formation of side products in the reductive amination approach for differential labeling of peptides in relative quantitative experiments. Electrophoresis, 2014, 35, 1259-1267.	2.4	1
65	Human recombinant domain antibodies against multiple sclerosis antigenic peptide CSF114(Glc). Journal of Molecular Recognition, 2014, 27, 618-626.	2.1	4
66	Immune Dysfunction in Rett Syndrome Patients Revealed by High Levels of Serum Anti-N(Glc) IgM Antibody Fraction. Journal of Immunology Research, 2014, 2014, 1-6.	2.2	18
67	Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Annals of the Rheumatic Diseases, 2014, 73, 1414-1422.	0.9	209
68	Epitope mapping of the N-terminal portion of tissue transglutaminase protein antigen to identify linear epitopes in celiac disease. Journal of Peptide Science, 2014, 20, 689-695.	1.4	4
69	1,4-Disubstituted-[1,2,3]triazolyl-Containing Analogues of MT-II: Design, Synthesis, Conformational Analysis, and Biological Activity. Journal of Medicinal Chemistry, 2014, 57, 9424-9434.	6.4	37
70	Biosensor analysis of anti-citrullinated protein/peptide antibody affinity. Analytical Biochemistry, 2014, 465, 96-101.	2.4	20
71	Surface plasmon resonance, fluorescence, and circular dichroism studies for the characterization of the binding of BACE-1 inhibitors. Analytical and Bioanalytical Chemistry, 2013, 405, 827-835.	3.7	17
72	Evaluation of new immunological targets in neuromyelitis optica. Journal of Peptide Science, 2013, 19, 25-32.	1.4	5

#	Article	IF	Citations
73	Divergent and convergent synthesis of polymannosylated dibranched antigenic peptide of the immunodominant epitope MBP(83â€“99). Bioorganic and Medicinal Chemistry, 2013, 21, 6718-6725.	3.0	12
74	Alpha Actinin is Specifically Recognized by Multiple Sclerosis Autoantibodies Isolated Using an N-Glucosylated Peptide Epitope. Molecular and Cellular Proteomics, 2013, 12, 277-282.	3.8	14
75	THU0093â€…Deiminated Histone 4 from Neutrophil Extracellular Traps is a Novel Autontigen in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A194.2-A194.	0.9	0
76	Glycopeptide-Based Antibody Detection in Multiple Sclerosis by Surface Plasmon Resonance. Sensors, 2012, 12, 5596-5607.	3.8	27
77	Di-(2-Ethylhexyl) Phthalate and Autism Spectrum Disorders. ASN Neuro, 2012, 4, AN20120015.	2.7	127
78	Solvent independent conformational propensities of [1,2,3]triazolylâ€bridged parathyroid hormoneâ€related peptideâ€derived cycloâ€nonapeptide analogues. Biopolymers, 2012, 98, 535-545.	2.4	3
79	Designed Glucopeptides Mimetics of Myelin Protein Epitopes As Synthetic Probes for the Detection of Autoantibodies, Biomarkers of Multiple Sclerosis. Journal of Medicinal Chemistry, 2012, 55, 10437-10447.	6.4	22
80	In vitroinhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain. Antiviral Therapy, 2011, 16, 905-913.	1.0	4
81	IgG and IgM antibodies to the refolded MOG1â€“125 extracellular domain in humans. Journal of Neuroimmunology, 2011, 233, 216-220.	2.3	8
82	Conventional and microwaveâ€assisted SPPS approach: a comparative synthesis of PTHrP(1â€“34)NH₂. Journal of Peptide Science, 2011, 17, 708-714.	1.4	23
83	Cu^Iâ€Catalyzed Azideâ€“Alkyne Intramolecular iâ€to‐(i+4) Sideâ€Chainâ€to‐Sideâ€Chain Cyclization Promotes the Formation of Helixâ€Like Secondary Structures. European Journal of Organic Chemistry, 2010, 2010, 446-457.	2.4	101
84	Posttranslationally modified peptides efficiently mimicking neoantigens: A challenge for theragnostics of autoimmune diseases. Biopolymers, 2010, 94, 791-799.	2.4	24
85	Building blocks for the synthesis of postâ€translationally modified glycated peptides and proteins. Journal of Peptide Science, 2009, 15, 67-71.	1.4	15
86	Side chainâ€to‐side chain cyclization by click reaction. Journal of Peptide Science, 2009, 15, 451-454.	1.4	38
87	Synthesis of new ribosylated Asn building blocks as useful tools for glycopeptide and glycoprotein synthesis. Tetrahedron Letters, 2009, 50, 4151-4153.	1.4	12
88	New Insight into the Binding Mode of Peptide Ligands at Urotensin-II Receptor: Structureâ^'Activity Relationships Study on P5U and Urantide. Journal of Medicinal Chemistry, 2009, 52, 3927-3940.	6.4	22
89	Side chain-to-Side chain Cyclization by Intramolecular Click Reaction - Building Blocks, Solid Phase Synthesis and Conformational Characterization. Advances in Experimental Medicine and Biology, 2009, 611, 175-176.	1.6	4
90	A Glycopeptide-based Technique for Selective Antibody Purification. Advances in Experimental Medicine and Biology, 2009, 611, 369-370.	1.6	0

#	Article	IF	Citations
91	Ribose Building Block For The Synthesis Of Glycopeptides For Fishing Out Antibodies In Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2009, 611, 441-442.	1.6	0
92	Studies for Identification of the Minimal Epitope(s) mimicked by the Synthetic Glucopeptide CSF114(Glc). Advances in Experimental Medicine and Biology, 2009, 611, 431-432.	1.6	0
93	Semi-Synthetic Strategies to Obtain Glucosylated MOG to Identify Antibodies as Biomarkers in Multiple Sclerosis Disease. Advances in Experimental Medicine and Biology, 2009, 611, 327-328.	1.6	0
94	N^{Î±}â€Fmocâ€Protected Ï‰â€Azidoâ€•and Ï‰â€Alkynylâ€<scp>L</scp>â€amino Acids as Building Blocks for the Synthesis of â€œClickableâ€•Peptides. European Journal of Organic Chemistry, 2008, 2008, 5308-5314.	2.4	30
95	Synthesis and Conformational Analysis of a Cyclic Peptide Obtained via i to i+4 Intramolecular Side-Chain to Side-Chain Azideâ^'Alkyne 1,3-Dipolar Cycloaddition. Journal of Organic Chemistry, 2008, 73, 5663-5674.	3.2	170
96	Structures and Micelle Locations of the Nonlipidated and Lipidated C-Terminal Membrane Anchor of 2â€²,3â€²-Cyclic Nucleotide-3â€²-phosphodiesterase. Biochemistry, 2008, 47, 308-319.	2.5	15
97	Designed Glycopeptides with Different Î²-Turn Types as Synthetic Probes for the Detection of Autoantibodies as Biomarkers of Multiple Sclerosis. Journal of Medicinal Chemistry, 2008, 51, 5304-5309.	6.4	28
98	Antibodies Generated in Cats by a Lipopeptide Reproducing the Membrane-Proximal External Region of the Feline Immunodeficiency Virus Transmembrane Enhance Virus Infectivity. Vaccine Journal, 2007, 14, 944-951.	3.1	12
99	Driving Forces in the Delivery of Penetratin Conjugated G Protein Fragment. Journal of Medicinal Chemistry, 2007, 50, 1458-1464.	6.4	9
100	Fmoc-protected iminosugar modified asparagine derivatives as building blocks for glycomimetics-containing peptides. Bioorganic and Medicinal Chemistry, 2007, 15, 3965-3973.	3.0	13
101	A Convenient Microwave-Enhanced Solid-Phase Synthesis of Difficult Peptide Sequences: Case Study of Gramicidin A and CSF114(Glc). International Journal of Peptide Research and Therapeutics, 2007, 13, 203-208.	1.9	54
102	Conformationâ^'Activity Relationship of Designed Glycopeptides as Synthetic Probes for the Detection of Autoantibodies, Biomarkers of Multiple Sclerosis. Journal of Medicinal Chemistry, 2006, 49, 5072-5079.	6.4	36
103	Electrochemical Investigation of Melittin Reconstituted into a Mercury-Supported Lipid Bilayer. Langmuir, 2006, 22, 6644-6650.	3.5	37
104	Physicochemical characterization of a peptide deriving from the glycoprotein gp36 of the feline immunodeficiency virus and its lipoylated analogue in micellar systems. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 1653-1661.	2.6	13
105	New Urotensin-II Analogs Modified at Position 4. , 2006, , 437-438.		0
106	Cross-Reactivity Studies of rMOGED with Synthetic Putative Autoantigens CSF114(Glc) and [N31(Glc)]hMOG(30â€“50) in Multiple Sclerosis Patientsâ€™ Sera. , 2006, , 769-770.		0
107	Does an Aberrant Glucosylation Trigger Autoimmunity in Multiple Sclerosis?. , 2006, , 775-776.		0
108	Optimization of Multiple Sclerosis Antigenic Probes by a Combinatorial Approach. , 2006, , 779-780.		0

#	Article	IF	Citations
109	Development of an Efficient Multiple Sclerosis Diagnostic Technology Based on an Optical Glycopeptide Immunosensor. , 2006, , 785-786.		1
110	Exploring interaction of Î²-amyloid segment (25â€“35) with membrane models through paramagnetic probes. Journal of Peptide Science, 2006, 12, 766-774.	1.4	24
111	Development of Antiviral Fusion Inhibitors: Short Modified Peptides Derived from the Transmembrane Glycoprotein of Feline Immunodeficiency Virus. ChemBioChem, 2006, 7, 774-779.	2.6	19
112	Urotensin-II Receptor Antagonists. Current Medicinal Chemistry, 2006, 13, 267-275.	2.4	26
113	A Membrane-Permeable Peptide Containing the Last 21 Residues of the GÎ±S Carboxyl Terminus Inhibits GS-Coupled Receptor Signaling in Intact Cells: Correlations between Peptide Structure and Biological Activity. Molecular Pharmacology, 2006, 69, 727-736.	2.3	19
114	Toward biomarkers in multiple sclerosis: new advances. Expert Review of Neurotherapeutics, 2006, 6, 781-794.	2.8	10
115	New Urotensin-II Analogs with a Constrained Trp-7 Side Chain. , 2006, , 439-440.		0
116	The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. Journal of Neuroimmunology, 2005, 167, 131-137.	2.3	56
117	GÎ±s proteinC-terminal Î±-helix at the interface: does the plasma membrane play a critical role in the GÎ±s protein functionality?. Journal of Peptide Science, 2005, 11, 617-626.	1.4	5
118	Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology, 2005, 65, 781-782.	1.1	23
119	An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10273-10278.	7.1	111
120	Urotensin-II Receptor Ligands. From Agonist to Antagonist Activity. Journal of Medicinal Chemistry, 2005, 48, 7290-7297.	6.4	24
121	N-Triazinylammonium Tetrafluoroborates. A New Generation of Efficient Coupling Reagents Useful for Peptide Synthesis. Journal of the American Chemical Society, 2005, 127, 16912-16920.	13.7	142
122	Synthesis of a Dicarba-Analog of Octreotide Keeping the Type II β -Turn of the Pharmacophore in Water Solution. Letters in Organic Chemistry, 2005, 2, 274-279.	0.5	15
123	Feline immunodeficiency virus plasma load reduction by a retroinverso octapeptide reproducing the Trp-rich motif of the transmembrane glycoprotein. Antiviral Therapy, 2005, 10, 671-80.	1.0	8
124	Feline Immunodeficiency Virus Plasma Load Reduction by a Retroinverso Octapeptide Reproducing the Trp-Rich Motif of the Transmembrane Glycoprotein. Antiviral Therapy, 2005, 10, 671-680.	1.0	14
125	The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology, 2004, 320, 156-166.	2.4	28
126	Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology, 2004, 322, 360-369.	2.4	11

#	Article	IF	Citations
127	On-resin head-to-tail cyclization of cyclotetrapeptides: optimization of crucial parameters. Journal of Peptide Science, 2004, 10, 218-228.	1.4	61
128	Urotensin-II receptor peptide agonists. Medicinal Research Reviews, 2004, 24, 577-588.	10.5	17
129	Urotensin-II Receptor Peptide Agonists. ChemInform, 2004, 35, no.	0.0	0
130	Unraveling the Active Conformation of Urotensin II. Journal of Medicinal Chemistry, 2004, 47, 1652-1661.	6.4	43
131	Recent Structure-Activity Studies of the Peptide Hormone Urotensin-II, a Potent Vasoconstrictor. Current Medicinal Chemistry, 2004, 11, 969-979.	2.4	18
132	A structureâ€“activity relationship study on position-2 of the GÎ±s C-terminal peptide able to inhibit Gs activation by A2A adenosine receptor. European Journal of Medicinal Chemistry, 2003, 38, 13-18.	5.5	8
133	Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. British Journal of Pharmacology, 2003, 140, 1155-1158.	5.4	92
134	Analysis of transglutaminase protein substrates by functional proteomics. Protein Science, 2003, 12, 1290-1297.	7.6	34
135	Retroinverso Analogue of the Antiviral Octapeptide C8 Inhibits Feline Immunodeficiency Virus in Serum. Journal of Medicinal Chemistry, 2003, 46, 1807-1810.	6.4	12
136	Antiviral Activity and Conformational Features of an Octapeptide Derived from the Membrane-Proximal Ectodomain of the Feline Immunodeficiency Virus Transmembrane Glycoprotein. Journal of Virology, 2003, 77, 3724-3733.	3.4	39
137	Synthetic Peptides in the Diagnosis of HIV Infection. Current Protein and Peptide Science, 2003, 4, 285-290.	1.4	23
138	Synthetic Peptides in the Diagnosis of Neurological Diseases. Current Protein and Peptide Science, 2003, 4, 277-284.	1.4	0
139	A New, Potent Urotensin II Receptor Peptide Agonist Containing a Pen Residue at the Disulfide Bridge. Journal of Medicinal Chemistry, 2002, 45, 4391-4394.	6.4	87
140	Structural Studies on Hgr3 Orphan Receptor Ligand Prolactin-Releasing Peptide. Journal of Medicinal Chemistry, 2002, 45, 5483-5491.	6.4	18
141	Efficacy of an Amphipathic Oligopeptide to Shuttle and Release a cis-Acting DNA Decoy into Human Cells. BioTechniques, 2002, 32, 172-177.	1.8	4
142	Assessment of new 6-Cl-HOBt based coupling reagents for peptide synthesis. Part 2: Racemization studies. International Journal of Peptide Research and Therapeutics, 2002, 9, 125-129.	0.1	1
143	Design, Synthesis, Conformational Analysis, and Biological Studies of Urotensin-II Lactam Analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3731-3739.	3.0	45
144	Synthesis and biological properties of the seven alanine-modified analogues of the marine cyclopeptide hymenamide C. Journal of Peptide Science, 2002, 8, 407-417.	1.4	5

#	Article	IF	Citations
145	Conformational analysis of the G?s proteinC-terminal region. Journal of Peptide Science, 2002, 8, 476-488.	1.4	8
146	Title is missing!. International Journal of Peptide Research and Therapeutics, 2002, 9, 119-123.	0.1	26
147	Title is missing!. International Journal of Peptide Research and Therapeutics, 2002, 9, 125-129.	0.1	5
148	Conformational Analysis of a Glycosylated Human Myelin Oligodendrocyte Glycoprotein Peptide Epitope Able To Detect Antibody Response in Multiple Sclerosis. Journal of Medicinal Chemistry, 2001, 44, 2378-2381.	6.4	36
149	Agonist Activity at the Kinin B1 Receptor:Â Structural Requirements of the Central Tetrapeptide. Journal of Medicinal Chemistry, 2001, 44, 274-278.	6.4	8
150	Synthesis, structural aspects and bioactivity of the marine cyclopeptide hymenamide C. Tetrahedron, 2001, 57, 6249-6255.	1.9	29
151	TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology. Journal of Medical Virology, 2001, 63, 189-195.	5.0	53
152	Conformational Studies of a Glycopeptide Recognized with High Affinity by Autoantibodies in Multiple Sclerosis. , 2001, , 340-341.		0
153	TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology. Journal of Medical Virology, 2001, 63, 189-95.	5.0	12
154	Conformational studies on a synthetic C-terminal fragment of the Î± subunit of GS proteins. Biopolymers, 2000, 54, 186-194.	2.4	11
155	A GÎ±sCarboxyl-Terminal Peptide Prevents GsActivation by the A2AAdenosine Receptor. Molecular Pharmacology, 2000, 58, 226-236.	2.3	39
156	A structure-activity study on the bradykinin B1 antagonist desArg10-HOE 140: The alanine scan. International Journal of Peptide Research and Therapeutics, 1999, 6, 123-127.	0.1	1
157	Calcium-mediated endothelin signaling in C6 rat glioma cells. Neuropeptides, 1999, 33, 13-17.	2.2	4
158	Synthesis and structureâ€“activity relationship studies of new endothelin pseudopeptide analogues containing alkyl spacers. Il Farmaco, 1999, 54, 213-217.	0.9	2
159	Design, synthesis, and conformational studies of the hGM-CSF derived peptide (13-27)-Gly-(75-87). Biopolymers, 1999, 50, 545-554.	2.4	0
160	A New Class of Pseudopeptide Antagonists of the Kinin B1 Receptor Containing Alkyl Spacers. Journal of Medicinal Chemistry, 1999, 42, 409-414.	6.4	27
161	Probing the Topological Arrangement of the N- and C-Terminal Residues of Bradykinin for Agonist Activity at the B1 Receptor. Journal of Medicinal Chemistry, 1999, 42, 3369-3377.	6.4	18
162	Racemization studies of Fmoc-Ser(tBu)-OH during stepwise continuous-flow solid-phase peptide synthesis. Tetrahedron Letters, 1998, 39, 8529-8532.	1.4	38

#	Article	IF	Citations
163	Toward the rational development of peptidomimetic analogs of the C-terminal endothelin hexapeptide: development of a theoretical model. Il Farmaco, 1998, 53, 545-556.	0.9	6
164	The Antiviral Activity of a Synthetic Peptide Derived from the Envelope SU Glycoprotein of Feline Immunodeficiency Virus Maps in Correspondence of an Amphipathic Helical Segment. Biochemical and Biophysical Research Communications, 1998, 246, 160-165.	2.1	6
165	Structure-Activity Analysis of C-Terminal Endothelin Analogues. Journal of Cardiovascular Pharmacology, 1998, 31, S251-S254.	1.9	8
166	Detection and epitope mapping of immunoreactive human endothelin-1 using ELISA and a surface plasmon resonance-based biosensor. Biosensors and Bioelectronics, 1997, 12, 765-778.	10.1	16
167	Synthesis and biological activity of new bradykinin pseudopeptide B1 receptor agonists containing alkylic spacers. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 2661-2664.	2.2	13
168	Design, synthesis and conformational analysis of hGM-CSF[13-31]-Gly-Pro-Gly-[103-116]. , 1997, 3, 323-335.		3
169	Conformation of four peptides corresponding to the Î±-helical segments of human GMâ€“CSF. , 1997, 3, 336-346.		5
170	SPPS of difficult sequences. Chemical Biology and Drug Design, 1997, 49, 103-111.	1.1	27
171	Putative odorant-binding protein in antennae and legs of carausius morosus (Insecta, Phasmatodea). Insect Biochemistry and Molecular Biology, 1996, 26, 19-24.	2.7	60
172	Mapping of Monoclonal Antibody- and Receptor-Binding Domains on Human Granulocyteâ€”Macrophage Colony-Stimulating Factor (rhGM-CSF) Using a Surface Plasmon Resonance-Based Biosensor. Hybridoma, 1996, 15, 343-350.	0.6	10
173	Binding of Human GM-CSF to Synthetic Peptides of the Alpha Subunit of Its Receptor. Journal of Receptor and Signal Transduction Research, 1996, 16, 77-92.	2.5	3
174	Inhibition of Feline Immunodeficiency Virus Infectionin Vitroby Envelope Glycoprotein Synthetic Peptides. Virology, 1996, 220, 274-284.	2.4	46
175	Investigation of Newly Synthesized Peptides by Capillary Zone Electrophoresis/Electrospray Mass Spectrometry. , 1996, 10, 1128-1132.		9
176	Investigation of Newly Synthesized Endothelin Peptides by High-performance Liquid Chromatography Coupled to Electrospray Mass Spectrometry. Rapid Communications in Mass Spectrometry, 1996, 10, 1504-1508.	1.5	6
177	Synthesis of the bradykinin B1 antagonist [desArg10]HOE 140 on 2-chlorotrityl resin. International Journal of Peptide Research and Therapeutics, 1996, 2, 319-323.	0.1	26
178	Facile reduction of peptide oxime endothelin antagonist during trialkylsilane/TFA cleavage after solid-phase synthesis. International Journal of Peptide Research and Therapeutics, 1996, 3, 117-120.	0.1	2
179	Peptide-based tachykinin NK2 receptor antagonists. Medicinal Research Reviews, 1995, 15, 139-155.	10.5	11
180	CD and fluorescence studies of the human granulocyte-macrophage colony-stimulating factor and related peptide conformations in aqueous solution. Biopolymers, 1995, 36, 1-8.	2.4	0

#	Article	IF	Citations
181	Solid-phase synthesis and dimerization of an azobenzene-containing peptide as photoisomerizable proteinase inhibitor. International Journal of Peptide Research and Therapeutics, 1995, 2, 27-32.	0.1	8
182	Differences in peptide-binding specificity of two ankylosing spondylitis-associated HLA-B27 subtypes. Immunogenetics, 1995, 42, 123-8.	2.4	13
183	Augmentation of the affinity of HLA class I-binding peptides lacking primary anchor residues by manipulation of the secondary anchor residues. Journal of Peptide Science, 1995, 1, 266-273.	1.4	7
184	GR 73,632 and [Glu(OBzl)11]substance P are selective agonists for the septide-sensitive tachykinin NK1 receptor in the rat urinary bladder. Neuropeptides, 1995, 28, 99-106.	2.2	9
185	Autoantibodies directed against ribosomal P proteins: use of a multiple antigen peptide as the coating agent in ELISA. Journal of Immunological Methods, 1995, 179, 193-202.	1.4	42
186	SPPS of difficult sequences: A comparison of chemical conditions, synthetic strategies and on-line monitoring. , 1995, , 254-255.		1
187	Further evaluation of the secondary anchor residues of HLA-B27-binding peptides. , 1995, , 813-814.		0
188	An Immunodominant Epitope in a Functional Domain Near the N-Terminus of Human Granulocyte-Macrophage Colony-Stimulating Factor Identified by Cross-Reaction of Synthetic Peptides with Neutralizing Anti-Protein and Anti-Peptide Antibodies. Hybridoma, 1994, 13, 457-468.	0.6	15
189	The peptide binding specificity of HLA-B27 subtypes. Immunogenetics, 1994, 40, 192-198.	2.4	34
190	Solid support-dependent alkylation of tryptophan residues in SPPS using a 2-methoxybenzyl alcohol-based linker. International Journal of Peptide Research and Therapeutics, 1994, 1, 149-155.	0.1	2
191	Synthesis and biological activity of NK1 substance P selective agonists by modifying the methionyl residue. Neuropeptides, 1994, 27, 27-29.	2.2	2
192	Synthesis and biological activity of NK1 tachykinin antagonists not containing D-residues. Neuropeptides, 1994, 26, 55-57.	2.2	3
193	The importance of secondary anchor residue motifs of HLA class I proteins: A chemometric approach. Molecular Immunology, 1994, 31, 549-554.	2.2	29
194	Solution conformation of câ€[Glnâ€Trpâ€Pheâ€Glyâ€Leuâ€Met], a NKâ€2 tachykinin antagonist. International Journal of Peptide and Protein Research, 1994, 44, 556-561.	0.1	3
195	Structure-Activity Relationships of Agonist and Antagonist Ligands. , 1994, , 329-365.		4
196	Rapid Simultaneous Determination of Tryptophan and Tyrosine in Synthetic Peptides by Derivative Spectroscopy. Journal of Pharmaceutical Sciences, 1993, 82, 179-182.	3.3	14
197	Side reactions in peptide synthesis: Dehydration of C-terminal aspartylamide peptides during side chain to side chain cyclization. Tetrahedron Letters, 1993, 34, 2199-2200.	1.4	6
198	HLA class I binding of synthetic nonamer peptides carrying major anchor residue motifs of HLA-B27 (B*2705)-binding peptides. Immunogenetics, 1993, 38, 41-46.	2.4	20

#	Article	IF	Citations
199	Tachykinin receptors and tachykinin receptor antagonists. Autonomic and Autacoid Pharmacology, 1993, 13, 23-93.	0.6	590
200	Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I Î± chains. Human Immunology, 1993, 38, 187-192.	2.4	22
201	A new endothelin c-terminal analogue IBDP 064 antagonizes endothelin-3-induced rat glioma cell proliferation. Biomedicine and Pharmacotherapy, 1993, 47, 249.	5.6	0
202	Anchor residue motifs of HLA class I-binding peptides analysed by the direct binding of synthetic peptides to HLA class I alpha chains. Human Immunology, 1993, 36, 67.	2.4	0
203	Conformation-activity relationship on MEN 10376 neurokinin A antagonist: Effect of cyclization. , 1993, , 591-592.		0
204	Structure-activity relationship of neurokinin A analogues as agonists at the NK2 receptor subtypes. , 1993, , 673-674.		0
205	Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors. Journal of Pharmacology and Experimental Therapeutics, 1993, 267, 590-5.	2.5	24
206	Role of C-terminal amidation on the biological activity of neurokinin A derivatives with agonist and antagonist properties. Journal of Pharmacology and Experimental Therapeutics, 1993, 264, 17-21.	2.5	14
207	N-terminal truncated analogs of men 10376 as tachykinin NK-2 receptor antagonists. Life Sciences, 1992, 51, 1929-1936.	4.3	4
208	Structure-Function analysis of human granulocyte-macrophage colony stimulating factor using synthetic peptides and antibodies. Pharmacological Research, 1992, 26, 192-193.	7.1	1
209	CGRP antagonist activity of short fragments of human Î±CGRP, CGRP(23â€“37) and CGRP(19â€“37). Peptides, 1992, 13, 1025-1027.	2.4	39
210	Structure-activity study of the C-terminal residue of MEN 10207 tachykinin antagonist. Peptides, 1992, 13, 207-208.	2.4	9
211	Activity of peptide and non-peptide antagonists at peripheral NK1 receptors. European Journal of Pharmacology, 1992, 215, 93-98.	3.5	40
212	[125I]His-neurokinin A binds selectively to NK2 receptors of the B-type in rat small intestine smooth muscle membranes. European Journal of Pharmacology, 1992, 227, 163-171.	2.6	4
213	Affinity of R 396, an NK-2 tachykinin receptor antagonist, for NK-2 receptors in preparations from different species. Neuropeptides, 1992, 22, 93-98.	2.2	18
214	Interaction of amyloid Î² protein (25â€“35) with tachykinin receptors. Neuropeptides, 1992, 22, 99-101.	2.2	19
215	Structure-activity relationship study of R396, an NK2 tachykinin antagonist selective for the NK2B receptor subtype. Neuropeptides, 1992, 23, 143-145.	2.2	6
216	Heterogeneity of tachykinin NK-2 receptors in rabbit, guinea-pig and human smooth muscles. Neuropeptides, 1992, 23, 181-186.	2.2	15

#	Article	IF	Citations
217	Importance of the C-terminal amide for the biological activity of neurokinin a derivatives. Neuropeptides, 1992, 22, 54.	2.2	1
218	Structure-activity study of R 396, an NK-2 receptor antagonist selective for the NK-2B receptor subtype. Neuropeptides, 1992, 22, 58-59.	2.2	0
219	Further evidence for the existence of NK₂ tachykinin receptor subtypes. British Journal of Pharmacology, 1991, 104, 91-96.	5.4	74
220	Conformation-activity relationship of tachykinin neurokinin A(4-10) and of some [Xaa8] analogs. Biochemistry, 1991, 30, 10175-10181.	2.5	28
221	Intracerebroventricular administration of endothelins: effects on the suprasptnal micturition reflex and blood pressure in the anaesthetized rat. European Journal of Pharmacology, 1991, 199, 201-207.	3.5	8
222	Tachykinin receptors in the guinea-pig isolated bronchi. European Journal of Pharmacology, 1991, 197, 167-174.	3.5	77
223	NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype. European Journal of Pharmacology, 1991, 203, 365-370.	3.5	69
224	Role of D-tryptophan for affinity of MEN 10207 tachykinin antagonist at NK2 receptors. Peptides, 1991, 12, 1015-1018.	2.4	14
225	Tachykinin Receptors and Noncholinergic Bronchoconstriction in the Guinea-Pig Isolated Bronchi. The American Review of Respiratory Disease, 1991, 144, 363-367.	2.9	99
226	NK-2 Receptor Agonists and Antagonists. Annals of the New York Academy of Sciences, 1991, 632, 184-191.	3.8	51
227	NKâ€1 Receptors and VascularPermeability in Rat Airways. Annals of the New York Academy of Sciences, 1991, 632, 358-359.	3.8	9
228	Effect of intrathecal administration of ET-1, ET-3 and ET(16â€“21) on blood pressure and micturition reflex in anesthetized rats. Neurochemistry International, 1991, 18, 565-569.	3.8	5
229	Tachykinin receptor antagonists and potential clinical applications at peripheral level. Biochemical Society Transactions, 1991, 19, 909-912.	3.4	15
230	Effect of synthetic tachykinin analogues on airway microvascular leakage in rats and guineaâ€pigs: evidence for the involvement of NKâ€1 receptors. Autonomic and Autacoid Pharmacology, 1991, 11, 267-276.	0.6	42
231	Synthesis of cyclic peptides on solid support. Tetrahedron Letters, 1991, 32, 2639-2642.	1.4	96
232	Solidâ€phase synthesis of neurokinin A antagonists. International Journal of Peptide and Protein Research, 1991, 37, 140-144.	0.1	18
233	Tachykinin Receptors in the Longitudinal and Circular Muscle of the Human Ileum. Advances in Experimental Medicine and Biology, 1991, 298, 249-252.	1.6	1
234	Comparison of Boc and Fmoc methods in the solid-phase synthesis of hydrophobic peptides. , 1991, , 179-180.		0

#	Article	IF	Citations
235	In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. Journal of Pharmacology and Experimental Therapeutics, 1991, 257, 1172-8.	2.5	103
236	Solid-phase synthesis of neurokinin A antagonists. Comparison of the Boc and Fmoc methods. International Journal of Peptide and Protein Research, 1991, 37, 140-4.	0.1	1
237	The Contractile Effect of Tachykinins on Human Prostatic Urethra: Involvement of NK-2 Receptors. Journal of Urology, 1990, 144, 1543-1545.	0.4	18
238	Structure-Activity Study of Neurokinins: Antagonists for the Neurokinin-2 Receptor. Pharmacology, 1990, 41, 184-194.	2.2	30
239	Chemometric approach to a QSAR study of peptides behaving as NK-2 receptor antagonists. Tetrahedron Computer Methodology, 1990, 3, 379-387.	0.2	9
240	Effect of endothelin-1, endothelin-3 and C-terminal hexapeptide, endothelin (16â€“21) on motor activity in rats. Neuropeptides, 1990, 16, 21-24.	2.2	24
241	Synthesis and biological activity of NK-2 selective tachykinin antagonists containing D-tryptophan. Peptides, 1990, 11, 619-620.	2.4	11
242	Analogs of neurokinin A(4â€“10) afford protection against gastroduodenal ulcers in rats. Peptides, 1990, 11, 293-297.	2.4	16
243	Evidence for heterogeneity off NK-2 tachykinin receptors by using competitive antagonists. European Journal of Pharmacology, 1990, 183, 2141-2142.	3.5	0
244	A highly selective NK-2 tachykinin receptor antagonist containing D-tryptophan. European Journal of Pharmacology, 1990, 175, 113-115.	3.5	51
245	Biological activity of N-terminal fragments of calcitonin gene-related peptide. European Journal of Pharmacology, 1990, 179, 217-219.	3.5	43
246	In vivo pharmacology of [Î²Ala8]neurokinin A-(4-10), a selective NK-2 tachykinin receptor agonist. European Journal of Pharmacology, 1990, 177, 81-86.	3.5	37
247	Structureâ€activity studies on endothelin (16â€“21), the Câ€terminal hexapeptide of the endothelins, in the guineaâ€pig bronchus. British Journal of Pharmacology, 1990, 101, 232-234.	5.4	24
248	Motor response of the human isolated small intestine and urinary bladder to porcine neuromedin Uâ€8. British Journal of Pharmacology, 1990, 99, 186-188.	5.4	43
249	Competitive antagonists discriminate between NK₂ tachykinin receptor subtypes. British Journal of Pharmacology, 1990, 100, 588-592.	5.4	164
250	Conformationally constrained tachykinins: N-methylated analogues of neurokinin A. Biopolymers, 1989, 28, 65-67.	2.4	5
251	Effects of tachykinins and selective tachykinin receptor agonists on vascular permeability in the rat lower urinary tract: evidence for the involvement of NKâ€1 receptors. Autonomic and Autacoid Pharmacology, 1989, 9, 253-264.	0.6	35
252	A potent and selective agonist for NK-2 tachykinin receptor. Peptides, 1989, 10, 593-595.	2.4	90

#	Article	IF	Citations
253	Tachykinins protect against ethanol-induced gastric lesions in rats. Peptides, 1989, 10, 79-81.	2.4	24
254	Further studies on the motor response of the human isolated urinary bladder to tachykinins, capsaicin and electrical field stimulation. General Pharmacology, 1989, 20, 663-669.	0.7	30
255	Structure-activity studies of neurokinin A. Neuropeptides, 1989, 13, 263-270.	2.2	105
256	The hamster isolated trachea: a new preparation for studying NK-2 receptors. European Journal of Pharmacology, 1989, 166, 435-440.	3.5	37
257	The C-terminal hexapeptide, endothelin-(16â€“21), discriminates between different endothelin receptors. European Journal of Pharmacology, 1989, 166, 121-122.	3.5	84
258	Effect of thiorphan on response of the guinea-pig gallbladder to tachykinins. European Journal of Pharmacology, 1989, 165, 51-61.	3.5	29
259	The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. European Journal of Pharmacology, 1989, 174, 23-31.	3.5	102
260	Effect of thiorphan on tachykinin-induced potentiation of nerve-mediated contractions of the rat isolated vas deferens. Journal of Pharmacology and Experimental Therapeutics, 1989, 250, 678-81.	2.5	28
261	NK-1 receptors mediate the tachykinin stimulation of salivary secretion: selective agonists provide further evidence. European Journal of Pharmacology, 1988, 150, 377-379.	3.5	37
262	Neurokinin A-(4â€“10): a potent bronchospastic agent virtually devoid of sialologic properties in anaesthetized guinea-pigs. European Journal of Pharmacology, 1988, 148, 475-478.	3.5	5
263	Contractile response of the human isolated urinary bladder to neurokinins: involvement of NK-2 receptors. European Journal of Pharmacology, 1988, 145, 335-340.	3.5	37
264	Effect of intravenous tachykinins and tachykinin -related peptides on vascular permeability in the rat lower urinary tract. Regulatory Peptides, 1988, 22, 27.	1.9	2
265	Tachykinins protect against ethanol induced gastric ulcers in rats. Regulatory Peptides, 1988, 22, 66.	1.9	1
266	Miotic effect of subtance P eye drops in humans. Regulatory Peptides, 1988, 22, 71.	1.9	1
267	Tachykinin receptors in the rat lower urinary tract. Regulatory Peptides, 1988, 22, 141.	1.9	0
268	Neurokinin receptors in the rat lower urinary tract. Journal of Pharmacology and Experimental Therapeutics, 1988, 246, 308-15.	2.5	49
269	Neurokinins induce a relaxation of the rat duodenum "in vivo" by activating postganglionic sympathetic elements in prevertebral ganglia: involvement of an NK-2 type of neurokinin receptor. Journal of Pharmacology and Experimental Therapeutics, 1988, 246, 322-7.	2.5	19
270	The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. European Journal of Pharmacology, 1987, 134, 321-326.	3.5	131

#	Article	IF	Citations
271	Synthesis and biological activity of N-methylated analogues of Neukokinin A. Neuropeptides, 1987, 10, 355-359.	2.2	12
272	Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels. European Journal of Pharmacology, 1986, 127, 219-224.	3.5	55
273	The actions of kinin antagonists on B1 and B2 receptor systems. European Journal of Pharmacology, 1986, 123, 61-65.	3.5	92
274	Synthesis and Rearrangement of Cycloadducts from Trimethylsilanecarbonitrile Oxide. Heterocycles, 1983, 20, 511.	0.7	15
275	Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis. Frontiers in Chemistry, 0, 10, .	3.6	0